Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1+ Selected TILs with Durvalumab and Tremelimumab in Melanoma
NCT04223648Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of PD-1+ selected tumor infiltrating lymphocytes in melanoma, sponsored by Yale University. Primary endpoint: PD1+ cell pharmacodynamic response in blood to tremelimumab/durvalumab treatment. Planned start Aug 2020; status: withdrawn.
02
Drugs
PD-1+ selected tumor infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04223648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04223648.